Alessio PIRAINO

Head of Global Marketed Products, AIR Franchise

Chiesi Farmaceutici SpA

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Alessio Piraino is the Head of Global Marketed Products at Chiesi Farmaceutici S.p.A. in Italy. His research focus encompasses chronic obstructive pulmonary disease (COPD), asthma, and their pharmacological treatments, as evidenced by his recent articles exploring immune responses in COPD and the implications of small airway dysfunction. He has contributed extensively to understanding therapeutic strategies, including fixed dose combinations and innovative treatment approaches in respiratory medicine.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (1)

Paola Brun

University of Padova

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alessio PIRAINO

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Decreased humoral immune response in the bronchi of rapid decliners with chronic obstructive pulmonary disease

Impulse Oscillometry, Small Airways Disease, and Extra-Fine Formulations in Asthma and Chronic Obstructive Pulmonary Disease: Windows for New Opportunities

The 5T approach in asthma: Triple Therapy Targeting Treatable Traits

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution

Reduced pulmonary function, low-grade inflammation and increased risk of total and cardiovascular mortality in a general adult population: Prospective results from the Moli-sani study

Narrative Analysis of the Impact of COVID-19 on Patients with Chronic Obstructive Pulmonary Disease, Their Caregivers, and Healthcare Professionals in Italy

Beclomethasone/Formoterol in Extra-Fine Formulation Improves Small Airway Dysfunction in COPD Patients

The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol

Extracorporeal Shock Waves Increase Markers of Cellular Proliferation in Bronchial Epithelium and in Primary Bronchial Fibroblasts of COPD Patients

Consequences of not-shaking and shake-fire delays on the emitted dose of some commercial solution and suspension pressurized metered dose inhalers

Collaborators (1)

Paola Brun

Make your next move.